New technologies in using recombinant attenuated Salmonella vaccine vectors

Area of Science:

• Microbiology
• Vaccinology
• Immunology

Background:

• Recombinant attenuated Salmonella vaccines (RASVs) deliver antigens to induce immunity.
• Effective RASVs must survive gastrointestinal transit and colonize lymphoid tissues without causing disease.
• Previous RASVs faced challenges with attenuation, antigen synthesis, and survival under stress.

Purpose of the Study:

• To develop improved RASVs with regulated delayed gene expression for enhanced efficacy and safety.
• To create a novel oral vaccine against Streptococcus pneumoniae using RASV technology.
• To ensure vaccine safety in newborns and infants and prevent environmental persistence.

Main Methods:

• Engineered RASVs with regulated delayed expression of attenuation and recombinant antigens.
• Incorporated a biological containment system with regulated delayed lysis.
• Added safety attributes to reduce side effects and ensure newborn safety.

Main Results:

• RASVs efficiently colonized lymphoid tissues, acting as antigen-producing "factories".
• Achieved higher protective immune responses compared to previous RASV constructs.
• Demonstrated safety in newborns and reduced incidence of mild diarrhea.
• Developed a novel, low-cost oral vaccine against multiple Streptococcus pneumoniae serotypes.

Conclusions:

• Regulated delayed expression enhances RASV colonization and antigen synthesis for superior immunogenicity.
• The novel RASV platform offers a safe and effective oral immunization strategy for newborns and infants.
• This technology provides a promising approach for developing broad-spectrum vaccines against bacterial pathogens like Streptococcus pneumoniae.